视网膜母细胞瘤
癌变
突变
抑癌基因
癌症研究
癌症
基因突变
生物
基因
机制(生物学)
肺癌
乳腺癌
遗传学
医学
肿瘤科
哲学
认识论
作者
Yiran Yao,Xiang Gu,Xiaofang Xu,Shengfang Ge,Renbing Jia
出处
期刊:Cancer Letters
[Elsevier BV]
日期:2022-08-11
卷期号:547: 215870-215870
被引量:34
标识
DOI:10.1016/j.canlet.2022.215870
摘要
Since the discovery of the retinoblastoma susceptibility gene (RB1) decades ago, RB1 has been regarded as a prototype tumor suppressor gene providing a paradigm for tumor genetic research. Constant research has updated the understanding of RB1-related pathways and their impact on tumor and nontumor diseases. Mutation of RB1 gene has been observed in multiple types of malignant tumors including prostate cancer, lung cancer, breast cancer, and almost every familial and sporadic case of retinoblastoma. Even if well-known and long-investigated, the application potential of RB1 mutation has not been fully tapped. In this review, we focus on the mechanism underlying RB1 mutation during oncogenesis. Therapeutically, we have further discussed potential clinical strategies by targeting RB1-mutated cancers. The unsolved problems and prospects of RB1 mutation are also discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI